Baseline vascularity may separate melasma responders from poor responders
A new prospective study at Allied Hospital-I in Faisalabad will test a practical question that dermatologists face every day: can baseline dermoscopic vascularity help predict who responds to oral tranexamic acid in facial melasma?
The trial is built around a simple clinical suspicion. Some patients with melasma improve briskly on therapy, while others show only modest change despite similar treatment. Investigators are now formalizing the idea that visible vascular involvement may mark a more treatment-resistant phenotype. If that signal holds, bedside dermoscopy could become more than a descriptive tool; it could help set expectations before a patient starts treatment.
A single-arm phase 4 design centered on dermoscopic phenotype
The study is an interventional, single-center, single-arm phase 4 protocol with prognostic-factor assessment. Every participant receives tranexamic acid 250 mg twice daily for 12 weeks, along with standardized photoprotection and skin care: a broad-spectrum SPF 50+ sunscreen in the morning and reapplied during the day, plus a plain ceramide-based emollient at night. No other depigmenting treatment is allowed during the study.
Rather than comparing tranexamic acid with placebo or another active drug, the study asks a narrower but clinically relevant question: does the amount of vascularity present before treatment predict the severity of melasma after therapy? The primary endpoint is week-12 modified Melasma Area and Severity Index, or mMASI, analyzed against a baseline dermoscopic vascular score.
The design keeps the clinical focus on the phenotype itself. Participants must be adults with facial melasma, Fitzpatrick skin type III, IV, or V, and a baseline mMASI of at least 4. Treatment-naive patients are eligible, as are those without topical or systemic melasma therapy for at least two weeks. The cohort excludes pregnancy, lactation, planned pregnancy, thromboembolic disease, thrombophilia, current estrogen exposure, anticoagulant use, renal impairment, active malignancy, recent major surgery, hypersensitivity to tranexamic acid, and several other facial pigmentary or inflammatory disorders that could cloud assessment.
Dermoscopy is being used as a prognostic instrument, not just a diagnostic camera
The most distinctive feature of the protocol is the way it operationalizes vascular assessment. In each affected facial region — forehead, right malar area, left malar area, and chin — one field in the most densely pigmented area is graded from 0 to 3 for erythema and telangiectatic vessels. Those scores are summed into a 0 to 12 vascular score, with prorating if fewer than four regions can be graded.
That scoring is performed with a DermLite DL4 in polarized contact mode after removal of cosmetics and sunscreen and a 5-minute rest. The protocol’s attention to preparation matters because it aims to reduce superficial noise from transient flushing or topical residue. The investigators are not trying to score every vessel on the face. They are trying to quantify the vascular signature most likely to influence treatment response.
A dermatologist who is unaware of the vascular score will score mMASI at each visit, and baseline and week-12 clinical grading are completed before dermoscopy at those time points. Stored baseline images will also be reviewed for inter-observer reliability in the first 40 participants. In a prognostic study like this, reproducibility is not a side issue; it is the foundation that determines whether the score can move beyond one clinic and one observer.
Tranexamic acid is being tested in a population where risk screening is part of the intervention
Because tranexamic acid carries thromboembolic concerns, the protocol builds safety screening directly into enrollment. Participants are assessed for thromboembolic risk before starting therapy and receive written instructions to stop treatment and seek attention if concerning symptoms arise. Serious adverse events are to be reported to the Ethical Review Committee. Rescue treatment is available if mMASI rises by 25% or more above baseline.
That safety framework is especially important here because the study is not limited to highly selected trial volunteers with a history of repeated exposure to the drug. The investigators are enrolling adults in routine dermatology care, which makes screening and follow-up essential. The study also excludes patients with renal impairment or elevated serum creatinine, an important safeguard because the drug is cleared renally and is generally used cautiously when kidney function is abnormal.
The statistical plan is built to answer a correlation question, not a treatment-comparison question
This is a precision-based study rather than a superiority trial. The target sample is 128 participants, with 102 complete datasets expected to provide a 95% confidence interval of total width 0.40 for the adjusted correlation. Missing week-12 outcomes will be addressed with multiple imputation, and prespecified sensitivity analyses will include adjustment for prior topical corticosteroid use.
The main analysis will use multiple linear regression to model week-12 mMASI against baseline vascular score, adjusting for baseline mMASI, duration of melasma, age, and Fitzpatrick skin type. In other words, the study is not asking whether tranexamic acid works in general. It is asking whether baseline vascularity explains how much improvement a patient is likely to achieve after a standardized 12-week course.
One sentence captures the study’s entire logic: the face may reveal more than pigment alone.
Why the result could matter in day-to-day dermatology practice
Melasma management often depends on educated trial and error. Patients want to know whether a course of oral therapy is likely to help, how long improvement may take, and whether the baseline appearance of the lesions says anything about prognosis. If a dermoscopic vascular score proves informative, it could become a fast office-based tool for counseling and patient selection.
The clinical appeal is easy to see. Patients with higher vascular scores may represent a subgroup in which vascular activity, not only melanogenesis, helps sustain visible disease. Tranexamic acid, by modulating pathways tied to plasmin activity and downstream signaling, may still help, but the magnitude of response could differ across phenotypes. The protocol does not assume that vascularity automatically means poor response. It is measuring whether that assumption is true.
The study’s limits are equally clear. It is single-center, open-label, and single-arm, so the findings will not establish comparative efficacy against another therapy. The 12-week window is also short for a chronic disorder that often relapses. Even so, the design is well suited to its stated purpose: separating a useful prognostic marker from a merely attractive hypothesis.
If the association is strong and reproducible, dermoscopic vascular scoring could become part of the initial workup for melasma patients considered for tranexamic acid. If the association is weak, clinicians may continue to rely on clinical severity, history, and response over time rather than vascular morphology at baseline. Either way, the study is aimed at an everyday question in skin-of-color dermatology, where treatment response is often variable and prediction remains imprecise.
For now, the central issue is straightforward: does a vascular-heavy dermoscopic pattern at baseline forecast a different 12-week outcome under standardized therapy? The trial at Allied Hospital-I is designed to find out.